Everolimus(RAD001), is a 40-O-(2-hydroxyethyl) derivative of rapamycin with immunosuppressant and anti-angiogenic properties, which exhibits improved aqueous solubility relative to the parent compound for oral administration. In cells, Everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of mTOR. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production

June 21, 2017

prudect name : Everolimus(RAD001), is a 40-O-(2-hydroxyethyl) derivative of rapamycin with immunosuppressant and anti-angiogenic properties, which exhibits improved aqueous solubility relative to the parent compound for oral administration.
In cells, Everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of mTOR. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production
Everolimus

Synonyms: CAS NO: 159351-69-6Molecular Formula: C₅₃H₈₃NO₁₄Molecular Weight: 958.22Purity: 98%Solubility: In DMSOStorage: −20°C 2 years

ONC-201 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18513921